Fig. 1
From: Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Synthesis and characterization of NICs. a Synthesis of P/mPEG5000(2%)/LLL(40%)/a-msTfR(0.2%)/a-CTLA-4 (0.2%). The upper structure represents the pre-conjugate and the lower structure represents the final nanoconjugate with antibodies and 3-(2-pyridyldithio) propionate (PDP). In some experiments, a-msTfR was substituted by AP-2 peptide (TFFYGGSRGKRNNFKTEEY). b SE-HPLC analysis of P/mPEG5000(2%)/LLL(40%)/a-msTfR(0.2%)/a-CTLA-4(0.2%). Right blue peak, the pre-conjugate P/mPEG5000(2%)/LLL(40%)/MEA(2%); middle (green) peak, a-CTLA-4; red peak, the synthesized P/mPEG5000(2%)/LLL(40%)/a-msTfR(0.2%)/a-CTLA-4(0.2%). c SE-HPLC analysis of P/mPEG5000(2%)/LLL(40%)/a-msTfR(0.2%)/a-PD-1(0.2%). Right blue peak, the pre-conjugate P/mPEG5000(2%)/LLL(40%)/MEA(2%); middle (green) peak, a-PD-1; red peak, the synthesized P/mPEG5000(2%)/LLL(40%)/a-msTfR(0.2%)/a-PD-1(0.2%). d and e Validation of simultaneous conjugation and activity of a-msTfR and a-CTLA-4/a-PD-1 on a single platform by ELISA of P/a-CTLA-4 d and P/a-PD-1 e. a-CTLA-4 and a-PD-1 (■), a-CTLA-4 and a-PD-1 on conjugate (◆), a-msTfR (●). f Illustration of ELISA method used in d. g Illustration of ELISA method used in e
